JP6512569B2 - 経皮投与用ｗｔ１ペプチド癌ワクチンテープ剤 - Google Patents

経皮投与用ｗｔ１ペプチド癌ワクチンテープ剤 Download PDF

Info

Publication number
JP6512569B2
JP6512569B2 JP2014014805A JP2014014805A JP6512569B2 JP 6512569 B2 JP6512569 B2 JP 6512569B2 JP 2014014805 A JP2014014805 A JP 2014014805A JP 2014014805 A JP2014014805 A JP 2014014805A JP 6512569 B2 JP6512569 B2 JP 6512569B2
Authority
JP
Japan
Prior art keywords
receptor
peptide
receptor agonist
acid
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014014805A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014169279A (ja
Inventor
佳己 前田
佳己 前田
大久保　勝之
勝之 大久保
大介 浅利
大介 浅利
有道 岡崎
有道 岡崎
卓矢 宍戸
卓矢 宍戸
光彦 堀
光彦 堀
治夫 杉山
治夫 杉山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nitto Denko Corp
The University of Osaka
Original Assignee
Nitto Denko Corp
Osaka University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corp, Osaka University NUC filed Critical Nitto Denko Corp
Priority to JP2014014805A priority Critical patent/JP6512569B2/ja
Publication of JP2014169279A publication Critical patent/JP2014169279A/ja
Application granted granted Critical
Publication of JP6512569B2 publication Critical patent/JP6512569B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014014805A 2013-02-05 2014-01-29 経皮投与用ｗｔ１ペプチド癌ワクチンテープ剤 Active JP6512569B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2014014805A JP6512569B2 (ja) 2013-02-05 2014-01-29 経皮投与用ｗｔ１ペプチド癌ワクチンテープ剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013020798 2013-02-05
JP2013020798 2013-02-05
JP2014014805A JP6512569B2 (ja) 2013-02-05 2014-01-29 経皮投与用ｗｔ１ペプチド癌ワクチンテープ剤

Publications (2)

Publication Number Publication Date
JP2014169279A JP2014169279A (ja) 2014-09-18
JP6512569B2 true JP6512569B2 (ja) 2019-05-15

Family

ID=50028734

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014014805A Active JP6512569B2 (ja) 2013-02-05 2014-01-29 経皮投与用ｗｔ１ペプチド癌ワクチンテープ剤

Country Status (8)

Country Link
US (1) US10195258B2 (enExample)
EP (1) EP2762156A1 (enExample)
JP (1) JP6512569B2 (enExample)
KR (1) KR102050931B1 (enExample)
CN (1) CN103961305B (enExample)
CA (1) CA2841014A1 (enExample)
IN (1) IN2014CH00393A (enExample)
RU (1) RU2697443C2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2565201B1 (en) 2005-10-17 2014-11-26 Sloan-Kettering Institute For Cancer Research WT1 HLA class II-binding peptides and compositions and methods comprising same
EP2010209B1 (en) 2006-04-10 2016-06-15 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
EP3520810A3 (en) 2012-01-13 2019-11-06 Memorial Sloan-Kettering Cancer Center Immunogenic wt1 peptides and use thereof
LT2945647T (lt) 2013-01-15 2021-02-25 Memorial Sloan Kettering Cancer Center Imunogeniniai wt-1 peptidai ir jų panaudojimo būdai
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
CN103961307B (zh) 2013-02-05 2019-11-29 日东电工株式会社 经皮给予用wt1肽癌症疫苗组合物
TW201618790A (zh) * 2014-10-02 2016-06-01 Nitto Denko Corp 經皮投與用疫苗醫藥組合物
DE102015119789A1 (de) * 2015-11-16 2017-05-18 Denso-Holding Gmbh & Co. Korrosionsschutzzusammensetzung umfassend Polyisobutylene
WO2022030631A1 (ja) * 2020-08-07 2022-02-10 株式会社 メドレックス 組み合わせ製剤
CN114712493B (zh) * 2022-04-29 2024-05-28 华南理工大学 一种疫苗递送载体及其制备方法和应用
CN120112559A (zh) * 2022-10-28 2025-06-06 百奥赛图(北京)医药科技股份有限公司 抗wt1/hla抗体及其应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
AU4932199A (en) 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
IL127331A0 (en) 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
RU2192884C2 (ru) 2000-11-09 2002-11-20 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Вакцина для стимуляции противоопухолевого иммунитета
US20040109869A1 (en) * 2001-03-19 2004-06-10 Iomai Corporation Transcutaneous immunostimulation
CN1281625C (zh) 2001-03-22 2006-10-25 株式会社癌免疫研究所 经修饰的wt1肽
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
WO2003106682A1 (ja) * 2002-06-12 2003-12-24 中外製薬株式会社 Ｈｌａ−ａ２４拘束性癌抗原ペプチド
ATE442378T1 (de) 2002-09-20 2009-09-15 Int Inst Cancer Immunology Inc Substituierte wt1-peptide
US20050215501A1 (en) * 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
WO2005045027A1 (ja) 2003-11-05 2005-05-19 International Institute Of Cancer Immunology, Inc. Ｗｔ１由来のｈｌａ−ｄｒ結合性抗原ペプチド
US8562988B2 (en) * 2005-10-19 2013-10-22 Ibc Pharmaceuticals, Inc. Strategies for improved cancer vaccines
WO2005089777A1 (en) 2004-03-15 2005-09-29 Karaolis David K R A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
PT1731605E (pt) 2004-03-31 2010-04-14 Int Inst Cancer Immunology Inc Péptidos antigénicos de cancro derivados de wt1
DE102004049223A1 (de) 2004-10-08 2006-04-20 Johannes-Gutenberg-Universität Mainz Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung
EP1782826A1 (en) 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
SI1961761T1 (sl) 2005-11-30 2010-12-31 Int Inst Cancer Immunology Inc Nove peptidne spojine iz Wilmsovega tumorja
RU2435782C2 (ru) 2006-02-22 2011-12-10 Интернешнл Инститьют Оф Кэнсер Иммунолоджи, Инк. Hla-a*3303-рестриктированный пептид wt1 и содержащая его фармацевтическая композиция
US20080112974A1 (en) 2006-09-08 2008-05-15 Duotol Ab Method for inducing mucosal humoral and cell-mediated immune responses by sublingual administration of antigens
JP4925039B2 (ja) 2006-09-21 2012-04-25 日東電工株式会社 糖材料の調製方法ならびに糖材料、糖材料を含むマイクロニードルおよびマイクロニードルをそなえてなる経皮製剤
JP2008127277A (ja) * 2006-11-16 2008-06-05 Osaka Prefectural Hospital Organization 免疫賦活化促進剤
RU2481398C2 (ru) 2006-12-28 2013-05-10 Интернешнл Инститьют Оф Кэнсер Иммунолоджи, Инк. Hla-a*1101-ограниченный пептид wt1 и содержащая его фармацевтическая композиция
JP5275047B2 (ja) 2007-01-31 2013-08-28 久光製薬株式会社 経皮または経粘膜投与のためのアジュバントおよびこれを含む医薬製剤
WO2009046738A1 (en) * 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
WO2009072610A1 (ja) * 2007-12-05 2009-06-11 International Institute Of Cancer Immunology, Inc. 癌ワクチン組成物
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
KR101329374B1 (ko) * 2008-12-09 2013-11-14 콜레이 파마시티컬 그룹, 인코포레이티드 면역자극성 올리고뉴클레오타이드
AR076349A1 (es) * 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
AU2010307075B2 (en) * 2009-10-12 2014-12-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Granulysin in immunotherapy
EP2868325B1 (en) * 2012-07-02 2017-11-01 Sumitomo Dainippon Pharma Co., Ltd. Transdermal cancer antigen peptide preparation
CN103961701B (zh) 2013-02-05 2018-09-14 日东电工株式会社 疫苗组合物
CA2840997A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition for transdermal administration
CN103961307B (zh) 2013-02-05 2019-11-29 日东电工株式会社 经皮给予用wt1肽癌症疫苗组合物

Also Published As

Publication number Publication date
US10195258B2 (en) 2019-02-05
RU2014102937A (ru) 2015-08-10
EP2762156A1 (en) 2014-08-06
US20140220105A1 (en) 2014-08-07
KR20140100421A (ko) 2014-08-14
RU2697443C2 (ru) 2019-08-14
CA2841014A1 (en) 2014-08-05
JP2014169279A (ja) 2014-09-18
CN103961305B (zh) 2019-10-18
KR102050931B1 (ko) 2019-12-02
CN103961305A (zh) 2014-08-06
IN2014CH00393A (enExample) 2015-04-03

Similar Documents

Publication Publication Date Title
JP6512567B2 (ja) 経皮投与用ｗｔ１ペプチド癌ワクチン組成物
JP6512568B2 (ja) 経皮投与用ｗｔ１ペプチド癌ワクチン組成物
CN103961305B (zh) 经皮给予用wt1肽癌症疫苗带状制剂
CN103961701B (zh) 疫苗组合物
JP2014169280A (ja) 経皮または粘膜投与用ワクチン組成物
JP6893075B2 (ja) 液性免疫誘導促進用組成物及びワクチン医薬組成物
JP2014169278A (ja) 経皮投与用ワクチン組成物
EP3189851A1 (en) Vaccine pharmaceutical composition for suppressing apoptosis of ctl or inhibiting suppression of induction of ctl

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150715

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171031

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180724

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181120

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190305

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190402

R150 Certificate of patent or registration of utility model

Ref document number: 6512569

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313114

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350